Your browser doesn't support javascript.
loading
Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation.
Del Chierico, Federica; Masi, Letizia; Petito, Valentina; Baldelli, Valerio; Puca, Pierluigi; Benvenuto, Roberta; Fidaleo, Marco; Palucci, Ivana; Lopetuso, Loris Riccardo; Caristo, Maria Emiliana; Carrozza, Cinzia; Giustiniani, Maria Cristina; Nakamichi, Noritaka; Kato, Yukio; Putignani, Lorenza; Gasbarrini, Antonio; Pani, Giovambattista; Scaldaferri, Franco.
Afiliação
  • Del Chierico F; Immunology, Rheumatology and Infectious Diseases Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Masi L; Department of Medical and Surgical Science, Digestive Disease Center (CeMAD) Translational Research Laboratories, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
  • Petito V; Department of Medical and Surgical Science, Digestive Disease Center (CeMAD) Translational Research Laboratories, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
  • Baldelli V; Immunology, Rheumatology and Infectious Diseases Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Puca P; Department of Medical and Surgical Sciences, UOS Inflammatory Bowel Diseases, Center for Diseases of Digestive System (CeMAD), Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Benvenuto R; Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.
  • Fidaleo M; Department of Pathology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
  • Palucci I; Department of Biology and Biotechnologies Charles Darwin, Università La Sapienza, Rome, Italy.
  • Lopetuso LR; Department of Basic Biotechnological Sciences, Intensive and Perioperative Clinics, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
  • Caristo ME; Institute of Microbiology, Catholic University of the Sacred Heart, Rome, Italy.
  • Carrozza C; Department of Medical and Surgical Sciences, UOS Inflammatory Bowel Diseases, Center for Diseases of Digestive System (CeMAD), Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Giustiniani MC; Department of Medicine and Ageing Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
  • Nakamichi N; Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
  • Kato Y; Cen.Ri.S Policlinico Gemelli UNICATT Rome, Rome, Italy.
  • Putignani L; Department of Clinical Biochemistry, Laboratory and Infectious Science, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
  • Gasbarrini A; Department of Pathology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
  • Pani G; Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, 370-0033, Takasaki, Gunma, Japan.
  • Scaldaferri F; Faculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
Inflamm Bowel Dis ; 2024 Jun 29.
Article em En | MEDLINE | ID: mdl-38944815
ABSTRACT

BACKGROUND:

Inflammatory bowel diseases are chronic disabling conditions with a complex and multifactorial etiology, still incompletely understood. OCTN1, an organic cation transporter, could have a role in modulating the inflammatory response, and some genetic polymorphisms of this molecule have been associated with increased risk of inflammatory bowel diseases. Until now, limited information exists on its potential in predicting/modulating patient's response to therapies. The aim of this study was to evaluate the role of OCTN1 in modifying gut microbiota and mucosal immunity in response to infliximab therapy in murine colitis.

METHODS:

A dextran sodium sulphate model of colitis was used to assess the clinical efficacy of infliximab administered intravenously in ocnt1 gene knockout mice and their C57BL/6 controls. Stool, colon, and mesenteric lymph node samples were collected to evaluate differences in gut microbiota composition, histology, and T cell populations, respectively.

RESULTS:

Octn1 -/- influences the microbiota profile and is associated with a worse dysbiosis in mice with colitis. Infliximab treatment attenuates colitis-associated dysbiosis, with an increase of bacterial richness and evenness in both strains. In comparison with wild type, octn1-/- mice have milder disease and a higher baseline percentage of Treg, Tmemory, Th2 and Th17 cells.

CONCLUSIONS:

Our data support the murine model to study OCTN1 genetic contribution to inflammatory bowel diseases. This could be the first step towards the recognition of this membrane transporter as a biomarker in inflammatory conditions and a predictor of response to therapies.
In this article, we evaluated the role of OCTN1, an organic cation transporter, in modifying gut microbiota and immune T cell populations, as well as its effects on experimental colitis and the response to infliximab treatment.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Inflamm Bowel Dis / Inflamm. bowel dis / Inflammatory bowel diseases Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Inflamm Bowel Dis / Inflamm. bowel dis / Inflammatory bowel diseases Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália